scholarly journals Viral Hepatitis and Hepatocellular Carcinoma: State of the Art

Pathogens ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1366
Author(s):  
Toofan Datfar ◽  
Michael Doulberis ◽  
Apostolis Papaefthymiou ◽  
Ian N. Hines ◽  
Giulia Manzini
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Molecular Mechanisms ◽  
Core Protein ◽  
Hepatitis D ◽  
Positive Hbsag ◽  
Risk Patients ◽  
Genotype C ◽  
Chronic Hcv

Viral hepatitis is one of the main causes leading to hepatocellular carcinoma (HCC). The continued rise in incidence of HCC suggests additional factors following infection may be involved. This review examines recent studies investigating the molecular mechanisms of chronic hepatitis and its association with hepatocarcinogenesis. Hepatitis B virus patients with genotype C display an aggressive disease course leading to HCC more than other genotypes. Furthermore, hepatitis B excretory antigen (HBeAg) seems to be a more sensitive predictive tumor marker exhibiting a six-fold higher relative risk in patients with positive HBsAg and HBeAg than those with HBsAg only. Single or combined mutations of viral genome can predict HCC development in up to 80% of patients. Several mutations in HBx-gene are related with higher HCC incidence. Overexpression of the core protein in HCV leads to hepatocellular lipid accumulation associated with oncogenesis. Reduced number and decreased functionality of natural killer cells in chronic HCV individuals dysregulate their surveillance function in tumor and viral cells resulting in HCC. Furthermore, high T-cell immunoglobulin and mucin 3 levels supress CD8+ T-cells, which lead to immunological dysregulation. Hepatitis D promotes HCC development indirectly via modifications to innate immunity, epigenetic alterations and production of reactive oxygen species with the LHDAg being the most highly associated with HCC development. Summarizing the results, HBV and HCV infection represent the most associated forms of viral hepatitis causing HCC. Further studies are warranted to further improve the prediction of high-risk patients and development of targeted therapeutics preventing the transition from hepatic inflammation–fibrosis to cancer.

scholarly journals Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ottovon Bismark Dakurah ◽  
Cynthia Raissa Tchuem Tamandjou ◽  
Moleen Zunza ◽  
Wolfgang Preiser ◽  
Tongai Gibson Maponga
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Web Of Science ◽  
African Continent ◽  
Inclusion Criteria ◽  
Hepatitis D ◽  
The Past ◽  
B Virus

Abstract Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in Africa. In Africa, the major causes of HCC include chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). Knowledge of the changes in the incidence of viral hepatitis-associated HCC over time and the factors responsible for such changes is key in informing policies for the prevention of viral hepatitis-associated HCC in Africa. Aim The study aimed to systematically summarize the changes in the prevalence of viral hepatitis among HCC patients and the overall effect of the prevalence of viral hepatitis on the incidence of HCC over the past four decades in Africa (1980–2019). Methods A literature search was conducted in MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Web of Science, and African wide web for articles published on viral hepatitis-associated HCC in Africa from 1980 to 2019. The abstracts of the articles were screened for eligibility and those meeting the inclusion criteria were retrieved and reviewed. Results A total of 272 studies were included in the analysis. Viral hepatitis-related HCC incidence changed by 1.17% (95% confidence interval (CI): 0.63–1.71, p < 0.001), 0.82% (95% CI: 0.45–1.18, p < 0.001), and 3.34% (95% CI: 2.44–4.25, p < 0.001) for every 1% change in the prevalence of HBV, HCV, and hepatitis D virus (HDV) respectively, per decade. The incidence of HBV-related HCC decreased by − 0.50% (95% CI: − 0.74 – − 0.25, p < 0.001) over the last 40 years, while HCV-related HCC increased. Conclusion Overall, the incidence of viral hepatitis-associated HCC has not declined, mainly due to no decline in the prevalence of HCV, HDV, and the high number of chronic hepatitis B carriers on the African continent. There is an urgent need for the allocation of resources for the implementation of treatment and preventive programs for HBV, HCV, HDV, and HCC in Africa. This systematic review is registered with PROSPERO®, number CRD42020169723.

Current Issues of Epidemiological Surveillance of Chronic Viral Hepatitis B, C, D and Hepatocellular Carcinoma at the Regional Level

2021 ◽  
pp. 76-84
Author(s):  
EV Khorkova ◽  
LV Lyalina ◽  
OM Mikailova ◽  
AYu Kovelenov ◽  
YuV Ostankova ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Hepatitis B ◽  
Epidemiological Surveillance ◽  
Leningrad Region ◽  
Hepatitis D ◽  
Viral Hepatitis B

Introduction. To achieve the goal of eliminating viral hepatitis by 2030, it is necessary to assess the real situation, improve epidemiological surveillance and prevention of these infections. Objectives: To evaluate the results of epidemiological surveillance of chronic viral hepatitis B, C, D and hepatocellular carcinoma in order to optimize the surveillance system at the regional level. Materials and methods: We analyzed the incidence of viral hepatitis B, C and liver cancer in the regions of the Northwestern and Central Federal Districts of the Russian Federation over the past 10 years. We also studied the prevalence of hepatitis B, C, D, and hepatitis C virus genotypes (6,020 cases), and examined 465 case histories of patients with hepatocellular carcinoma in the Leningrad Region using techniques of epidemiological analysis, ELISA, PCR, and statistical methods. Results: We established a tendency towards a decrease in the incidence of chronic hepatitis B and C in all study areas. In 2020, high rates of hepatitis B (26.2 and 9.1) and hepatitis C (49.2 and 39.2) were registered in St. Petersburg and Moscow per 100,000 population, respectively. The prevalence of hepatitis D in the Leningrad Region was 6.3 per 100,000 population. Hepatitis C virus genotypes 1 and 3 prevailed (48.9 % and 43.9 %, respectively). A high incidence of liver cancer was established in St. Petersburg, the Pskov and Novgorod Regions. Conclusions: Our findings prove the efficiency of the surveillance system and prevention of chronic hepatitis B and C. The main objectives are to further reduce the incidence rate, screen all patients with chronic hepatitis B for hepatitis D, and use the results of molecular genetic studies and cancer registries for epidemiological surveillance purposes.

scholarly journals ESTRATEGIAS PARA LA ERRADICACIÓN MUNDIAL DE LA HEPATITIS VIRAL CRÓNICA PARA EL 2030

2020 ◽  
Vol 5 (4) ◽  
pp. 45
Author(s):  
Edgardo Mengual-Moreno ◽  
Maribel Lizarzábal-García ◽  
Orlando J. Penaloza
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Diagnostic Methods ◽  
World Health ◽  
Post Exposure Prophylaxis ◽  
Hepatitis D

Los virus de hepatitis B (VHB), C (VHC) y D (VHD); producen hepatitis viral crónica (HVC) responsable de 1.4 millones de muertes por cirrosis hepática y carcinoma hepatocelular. La Organización Mundial de la Salud, adoptó estrategias para la eliminación del VHC para el año 2030. La vacunación contra el VHB reduce el 80% de muertes, previene la HVC por VHB, VHD y el carcinoma hepatocelular. La prevención de la transmisión vertical es una estrategia 90% útil para detener la HVC en hijos de madres infectadas con el VHB. El uso apropiado de inyecciones, pesquisaje adecuado de la sangre de dotantes y la selección restrictiva de donantes disminuye el riesgo de VHC. Las medidas de reducción de daño de HVC consisten en proporcionar jeringas estériles a adictos, prevención de accidentes por pinchazos en personal de salud, introducción de dispositivos de seguridad para la prevención de lesiones punzantes, vacunación de todos los trabajadores de la salud y profilaxis posterior a accidentes laborales. El diagnóstico correcto de VHB permitirá instaurar el tratamiento disponible no curativo, mientras que la terapia antiviral de acción directa cura la hepatitis C. El uso de preservativos y nuevos métodos diagnósticos podrían ser estrategias útiles de prevención de HVC. Palabras claves: hepatitis B, hepatitis C, hepatitis D, hepatitis viral crónica, cirrosis hepática, erradicación. ABSTRACT Chronic viral hepatitis (CVH) associated with Hepatitis B (HBV), C (HCV) and D (HDV) viruses are responsible for 1.4 million deaths from liver cirrhosis and hepatocellular carcinoma. The World Health Organization has implemented strategies for the elimination of HCV by 2030. Vaccination against HBV reduces 80% of deaths and prevents CVH associated with HBV, HDV, and hepatocellular carcinoma. The prevention of perinatal vertical transmission is the most appropriate strategy to avoid CVH by 90% in children of HBV infected mothers. The use of injections appropriately, the screening of blood from donors, and restrictive donor selection decrease the risk of HCV. CVH harm reduction consist of providing sterile syringes to people who inject drugs (PWID), prevention of accidental puncture in health personnel, introduction of safety devices for the prevention of puncture injuries, vaccination against HBV of all health workers and post-exposure prophylaxis after work related accidents. The correct diagnosis of HBV, will allow the introduction of available non-curative treatment, while direct-acting antiviral therapy cures hepatitis C. The use of condoms and new diagnostic methods could be useful strategies for preventing HCV. Keywords: hepatitis B, hepatitis C, hepatitis D, chronic viral hepatitis, liver cirrhosis, eradication.

scholarly journals Viral Hepatitis Associated Hepatocellular Carcinoma on the African Continent, The Past, Present, and Future: A Systematic Review.

2021 ◽  
Author(s):  
Ottovon Bismark Dakurah ◽  
Cynthia Raissa Tchuem Tamandjou ◽  
Moleen Zunza ◽  
Wolfgang Preiser ◽  
Tongai Gibson Maponga
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Web Of Science ◽  
African Continent ◽  
Inclusion Criteria ◽  
Hepatitis D ◽  
The Past ◽  
B Virus

Abstract Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in Africa. In Africa, the major causes of HCC include chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). Knowledge of the changes in the incidence of viral hepatitis-associated HCC over time and the factors responsible for such changes is key in informing policies for the prevention of viral hepatitis-associated HCC in Africa. Aim: The study aimed to systematically summarize the changes in the incidence of viral hepatitis-associated HCC in Africa over a four-decade period (1980-2020).Methods: A literature search was conducted in MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Web of Science, and African wide web for articles published on viral hepatitis-associated HCC in Africa from 1980-2020. The abstracts of the articles were screened for eligibility and those meeting the inclusion criteria were retrieved and reviewed.Results: A total of 272 studies were included in the analysis. Viral hepatitis-related HCC incidence changed by 1.17% (95% confidence interval (CI): 0.63 – 1.71, p < 0.001), 0.82% (95% CI: 0.45 – 1.18, p < 0.001), and 3.34% (95% CI: 2.44 – 4.25, p < 0.001) for every 1% change in the prevalence of HBV, HCV, and hepatitis D virus (HDV) respectively, per decade. The incidence of HBV-related HCC changed significantly by -0.50% (95% CI: -0.74 – -0.25, p < 0.001) over the last 40 years, while HCV-related HCC increased.Conclusion: Overall, the incidence of viral hepatitis-associated HCC has not declined, mainly due to no decline in the prevalence of HCV, HDV, and the high number of chronic hepatitis B carriers on the African continent. There is an urgent need for the allocation of resources for the implementation of treatment and preventive programs for HBV, HCV, HDV, and HCC in Africa.This systematic review is registered with PROSPERO®, number CRD42020169723.

Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma

2009 ◽  
Vol 150 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Alajos Pár
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Mivel a hepatitis B- és C-vírus- (HBV-, HCV-) fertőzés döntő szerepet játszik a hepatocellularis carcinoma (HCC) keletkezésében, a HBV és HCV okozta hepatitis és cirrhosis megelőzése és kezelése egyben a HCC prevencióját is jelentheti. A HCC primer prevencióját képviseli a HBV elleni vakcináció és a donorok szűrése HBV- és HCV-markerekre. A szekunder prevencióhoz sorolható az interferonalapú és/vagy nukleozidanalóg anti-HBV- és anti-HCV-terápia, a cirrhosisos betegek HCC irányában történő alfa-foetoprotein + ultrahang szűrése, valamint a HCC kuratív reszekciója/ablatiója utáni adjuváns antivirális kezelés. Várható, hogy a HBV-vakcináció világszerte történő széles körű alkalmazása, továbbá az optimalizált individuális antivirális kezelésmódok, az új nukleozidanalógok és HCV-specifikus proteáz- és polimerázgátlók révén előrelépés történik nemcsak a vírushepatitisek megelőzésében és terápiájában, hanem a HCC prevenciójában is a nem túl távoli jövőben.

scholarly journals Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 862
Author(s):  
Yueh-Te Lin ◽  
Long-Bin Jeng ◽  
Wen-Ling Chan ◽  
Ih-Jen Su ◽  
Chiao-Fang Teng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Molecular Mechanisms ◽  
Incidence Rates ◽  
Gene Deletions ◽  
S Gene ◽  
B Virus ◽  
Potential Applications ◽  
Prevention And Therapy

Hepatocellular carcinoma (HCC) is one of the most frequent and fatal human cancers worldwide and its development and prognosis are intimately associated with chronic infection with hepatitis B virus (HBV). The identification of genetic mutations and molecular mechanisms that mediate HBV-induced tumorigenesis therefore holds promise for the development of potential biomarkers and targets for HCC prevention and therapy. The presence of HBV pre-S gene deletions in the blood and the expression of pre-S deleted proteins in the liver tissues of patients with chronic hepatitis B and HBV-related HCC have emerged as valuable biomarkers for higher incidence rates of HCC development and a higher risk of HCC recurrence after curative surgical resection, respectively. Moreover, pre-S deleted proteins are regarded as important oncoproteins that activate multiple signaling pathways to induce DNA damage and promote growth and proliferation in hepatocytes, leading to HCC development. The signaling molecules dysregulated by pre-S deleted proteins have also been validated as potential targets for the prevention of HCC development. In this review, we summarize the clinical and molecular implications of HBV pre-S gene deletions and pre-S deleted proteins in HCC development and recurrence and highlight their potential applications in HCC prevention and therapy.

Viral Hepatitis: 1985 Update

1985 ◽  
Vol 7 (1) ◽  
pp. 3-11
Author(s):  
Saul Krugman
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis A ◽  
Viral Infections ◽  
Hepatitis A Virus ◽  
Fatal Outcome ◽  
Specific Marker ◽  
Hepatitis D ◽  
B Virus

During the past two decades extraordinary advances in hepatitis research have clarified the etiology and natural history of the disease. At least four types of hepatitis have been identified: A, B, D (delta), and non-A, non-B. Hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis D virus (HDV) have been characterized. Serologic tests have been developed to detect the antigens and antibodies associated with these three hepatitis infections. As of the present time, the non-A, non-B viral agents have not been identified. Therefore, non-A, non-B hepatitis is diagnosed by excluding other viral causes of hepatitis, such as hepatitis A virus, hepatitis B virus, Epstein-Barr virus (EBV), cytomegalovirus (CMV), and others. A recent report indicating that non-A, non-B hepatitis may be caused by a retrovirus, if confirmed, may provide a specific marker of this infection. The course of viral hepatitis is variable; it may be an asymptomatic, anteric infection, or it may be an acute illness characterized by fever, malaise, anorexia, nausea, abdominal pain, and jaundice. Most patients recover completely, but occasionally the infection may be complicated by chronic hepatitis, cirrhosis, and, occasionally, by a fulminant fatal outcome. This review will be devoted predominantly to a discussion of the diagnostic and prophylactic aspects of hepatitis A and hepatitis B viral infections.

Viral Hepatitis Other than A, B, or C

2016 ◽  
Author(s):  
Nadeem Anwar ◽  
Kenneth E. Sherman
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hepatitis E Virus ◽  
Hepatitis Virus ◽  
Cell Damage ◽  
Hepatitis E ◽  
Hepatitis D ◽  
Hepatitis D Virus ◽  
Treatment And Prevention ◽  
Key Words Hepatitis

Viral hepatitis is a global, although variably distributed, health problem associated with significant morbidity and mortality. Infection with a hepatitis virus leads to acute inflammation and liver cell damage (hepatocyte injury). Such infection may be symptomatic or subclinical and may result in disease resolution, death from fulminant hepatic failure, or development of  a chronic disease state. Whereas the chronic infection with hepatitis B and C accounts for a global burden of more than 500,000,000 cases, the global death rate from all types of hepatitis is approximately 1 million people annually. This review focuses on the virology, epidemiology, clinical features, diagnosis, treatment, and prevention of hepatitis D and hepatitis E, as well as other viruses associated with hepatitis. Figures show the global distribution of hepatitis D infection, elevation of anti–hepatitis D virus antibodies in hepatitis B/hepatitis D virus coinfection, geographic distribution of hepatitis E virus by genotype, factors significant in the pathogenesis of hepatitis E, and pattern of antibody elevation in hepatitis E. The table lists proposed diagnostic criteria for hepatitis E virus. This review contains 5 highly rendered figures, 1 table, and 42 references. Key words: hepatitis D, hepatitis D virus, hepatitis E, hepatitis E virus, non-A hepatitis, non-B hepatitis, non-C hepatitis, viral hepatitis 

scholarly journals Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

2022 ◽  
Vol 23 (1) ◽  
pp. 500
Author(s):  
Francesco Paolo Russo ◽  
Alberto Zanetto ◽  
Elisa Pinto ◽  
Sara Battistella ◽  
Barbara Penzo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Virological Suppression ◽  
Risk Patients ◽  
Related Liver Disease ◽  
Direct Acting ◽  
Cell Signaling Pathways

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death. Although the burden of alcohol- and NASH-related HCC is growing, chronic viral hepatitis (HBV and HCV) remains a major cause of HCC development worldwide. The pathophysiology of viral-related HCC includes liver inflammation, oxidative stress, and deregulation of cell signaling pathways. HBV is particularly oncogenic because, contrary to HCV, integrates in the cell DNA and persists despite virological suppression by nucleotide analogues. Surveillance by six-month ultrasound is recommended in patients with cirrhosis and in “high-risk” patients with chronic HBV infection. Antiviral therapy reduces the risks of development and recurrence of HCC; however, patients with advanced chronic liver disease remain at risk of HCC despite virological suppression/cure and should therefore continue surveillance. Multiple scores have been developed in patients with chronic hepatitis B to predict the risk of HCC development and may be used to stratify individual patient’s risk. In patients with HCV-related liver disease who achieve sustained virological response by direct acting antivirals, there is a strong need for markers/scores to predict long-term risk of HCC. In this review, we discuss the most recent advances regarding viral-related HCC.

Sign in / Sign up

Export Citation Format

Share Document